The U.S. Patent and Trademark Office has granted Digital Angel Corporation a patent for its syringe-implantable glucose-sensing RFID microchip, Digital Angel announced today. The RFID microchip measures the glucose concentration levels of diabetic patients and will be marketed and distributed by Digital Angel's sister company, VeriChip, as an extension to the company's products benefiting people. "A glucose-sensing microchip could profoundly impact the 230 million people worldwide living with diabetes," said Digital Angel CEO and President, Kevin McGrath. "Patent approval for this RFID microchip is a major step in bringing this life-altering technology to market. It also underscores Digital Angel's commitment...
